SOUTH JORDAN, Utah, March 05, 2024 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ: MMSI), a global leader of healthcare technology, announced today a series of events for clinicians attending the 2024 SIR Annual Meeting. These educational events will take place at Merit’s headquarters and at SIR booth 320.
On March 26, Merit will host an Evening of Innovation at its Salt Lake City headquarters from 6:30 p.m.– 9:00 p.m. During the evening, guests will hear from Merit’s Chairman and CEO, Fred Lampropoulos, attend a reception, tour Merit’s manufacturing facility, and learn firsthand about Merit’s history of innovation.
Throughout SIR, Merit will host the following educational events at booth 320:
Register for these educational events.
“We welcome SIR and its members to Salt Lake City, home of Merit’s corporate headquarters and where Merit was founded thirty-seven years ago,” said Mr. Lampropoulos. “As a supporter of SIR, we share the organization’s commitment to educational opportunities and clinical research to advance the practice of interventional radiology. We are excited to share Merit’s full scope of interventional radiology offerings and solutions with this distinguished audience, furthering our mission to improve patient lives."
ABOUT MERIT MEDICAL Founded in 1987, Merit Medical Systems, Inc. is engaged in the development, manufacture, and distribution of proprietary disposable medical devices used in interventional, diagnostic, and therapeutic procedures, particularly in cardiology, radiology, oncology, critical care, and endoscopy. Merit serves client hospitals worldwide with a domestic and international sales force and clinical support team totaling more than 700 individuals. Merit employs approximately 7,000 people worldwide.
TRADEMARKS Unless noted otherwise, trademarks and registered trademarks used in this release are the property of Merit Medical Systems, Inc., its subsidiaries, or its licensors.
CONTACTS
PR/Media Inquiries
Sarah Comstock
Merit Medical
+1-801-432-2864 | This email address is being protected from spambots. You need JavaScript enabled to view it.
INVESTOR INQUIRIES
Mike Piccinino, CFA, IRC
Westwicke - ICR
+1-443-213-0509 | This email address is being protected from spambots. You need JavaScript enabled to view it.
Last Trade: | US$83.21 |
Daily Change: | 1.35 1.65 |
Daily Volume: | 313,365 |
Market Cap: | US$4.930B |
October 15, 2025 October 01, 2025 September 12, 2025 August 18, 2025 August 07, 2025 |
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MOREAmneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...
CLICK TO LEARN MOREEnd of content
No more pages to load